SCHEMBL2007293

SCHEMBL2007293

Cc1cc(O)ccc1-c1nc2ccccc2c(=O)n1C

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CASR P41180 2/20 0.51
ALDH1A1 P00352 4/20 0.50
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
MAPT P10636 2/20 0.50
HSD17B10 Q99714 1/20 0.50
ALOX12 P18054 1/20 0.50
MAPK10 P53779 1/20 0.50
ATM Q13315 1/20 0.50
BACE1 P56817 1/20 0.49
GAA P10253 3/20 0.49
KDM4E B2RXH2 4/20 0.49
LMNA P02545 1/20 0.48
GFER P55789 1/20 0.47
ESR2 Q92731 1/20 0.46
TDO2 P48775 3/20 0.46
IDO2 Q6ZQW0 3/20 0.46
IDO1 P14902 2/20 0.45
MAPK1 P28482 1/20 0.45
PDE5A O76074 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1462891 0.78 ESR1 (0.58) CASRALDH1A1MEN1KMT2AMAPT
SCHEMBL22720142 0.76 KDM4E (0.57) ALDH1A1MEN1KMT2AMAPTKDM4E
SCHEMBL1463333 0.75 KMT2A (0.65) CASRALDH1A1MEN1KMT2AMAPT
SCHEMBL29764078 0.75 KMT2A (0.65) CASRALDH1A1MEN1KMT2AMAPT
SCHEMBL11445400 0.74 ALDH1A1 (0.78) ALDH1A1MAPTHSD17B10GAAKDM4E
SCHEMBL22736778 0.73 ALDH1A1 (0.60) ALDH1A1MEN1KMT2AMAPTGAA
SCHEMBL2008223 0.73 HRH3 (0.53)
SCHEMBL23743247 0.73 POLB (0.57) ALDH1A1MEN1KMT2AKDM4ELMNA
SCHEMBL28639674 0.73 KMT2A (0.57) ALDH1A1MEN1KMT2AMAPTKDM4E
SCHEMBL2006508 0.72 HRH3 (0.74)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7960394-B2 3,8-dimethyl-2-[4-(3-piperidin-1-ylpropoxy)phenyl]-4(3H)-quinazolinone; 6-chloro-3-methyl-2-[4-(3-piperidin-1-ylpropoxy)phenyl]pyrido[3,4-d]-pyrimidin-4(3H)-one; 2-[4-(1-cyclopentyl-4-piperidinyloxy)phenyl]-3-methylpyrido[2,3-d]-pyrimidin-4(3H)-one; treats metabolic, nervous system, vascular disorders BANYU PHARMACEUTICAL CO., LTD. (JP) 2011-06-14 US disclosed
US-20080275069-A1 Quinazoline Derivative MSD K.K. (JP) 2008-11-06 US disclosed
CN-1960977-A Quinazoline derivative BANYU PHARMA CO LTD (JP) 2007-05-09 CN disclosed
EP-1757594-A1 QUINAZOLINE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2007-02-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080275069-A1 Quinazoline Derivative HRH3, HRH4, HRH2 CASR 616/4885ALDH1A1 2782/4885MEN1 1737/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.